



ASX & MEDIA RELEASE

6 MARCH 2017

MEDLAB SIGNS AGREEMENT TO START COMPARISON STUDY FOR STATINS, CHOLESTEROL LOWERING DRUG

Medical life science company, Medlab Clinical Limited (ASX: MDC), has signed an agreement to initiate a study to compare how its NanoCelle™ Atorvastatin oral spray, called “NanoStat”, patent pending, compares with taking statin tablets, like Lipitor, the off patent market leader.

The size of the statins market worldwide, predominantly comprised of tablets, is significant and has been estimated at US\$12 billion in 2018¹.

Medlab’s research to date indicates that a more direct oral spray will enable smaller doses and by reducing dosage, remove much of the statin side effects, reported by approximately one-third of patients, predominantly experiencing some form of pain.

According to Medlab CEO, Sean Hall, testing of Nanocelle™ with statins in the lab had been promising but an independent study was required to provide objective evidence for those pharma companies which had shown an interest to date.

“Positive outcomes would lead to growing market interest in this development and wider application of the technology to other major off patent drugs,” Mr Hall said.

Medlab’s study agreement is with Zenith Technology Corporation of Dunedin New Zealand, a certified research organisation which does clinical trials and analysis to recognised international pharmaceutical industry standards.

Guidance on TGA biopharmaceutic studies, including bio-equivalence, can be found here: <https://www.tga.gov.au/sites/default/files/guidance-15-biopharmaceutic-studies.pdf>

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: MR SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ISSUED BY: HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL
TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, with a certified biologics facility in Sydney and sales arms in Australia and California. Medlab’s research relates to five health areas - obesity, chronic kidney disease, depression, ageing and muscular skeletal health and pain management. A lot of Medlab’s research is on the role bacteria in the gastrointestinal tract play in health and disease, leading to drug discovery and development of new medicines involving bacteria (pharmacobiotics) as well as nutritional products. Medlab is also about to commence a human trial of a cannabis-based medicine for oncology patients with intractable pain, utilising its small particle medicine delivery system, Nanocelle™. Medlab has a growing patent portfolio, multiple published research papers and conference presentations and the Pharmacobiotic trademark – a therapeutic term referring to both probiotics and biologics.

¹ Research report news release, <http://www.prweb.com/releases/statins-drugs-market/analysis-forecast-2018/prweb10367278.htm>